Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 274

1.

ERF deletion rescues RAS deficiency in mouse embryonic stem cells.

Mayor-Ruiz C, Olbrich T, Drosten M, Lecona E, Vega-Sendino M, Ortega S, Dominguez O, Barbacid M, Ruiz S, Fernandez-Capetillo O.

Genes Dev. 2018 Apr 1;32(7-8):568-576. doi: 10.1101/gad.310086.117. Epub 2018 Apr 12.

PMID:
29650524
2.

The Capicua tumor suppressor: a gatekeeper of Ras signaling in development and cancer.

Simón-Carrasco L, Jiménez G, Barbacid M, Drosten M.

Cell Cycle. 2018 Mar 26:1-33. doi: 10.1080/15384101.2018.1450029. [Epub ahead of print]

PMID:
29578365
3.

Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.

Gao Y, Chang MT, McKay D, Na N, Zhou B, Yaeger R, Torres NM, Muniz K, Drosten M, Barbacid M, Caponigro G, Stuart D, Moebitz H, Solit DB, Abdel-Wahab O, Taylor BS, Yao Z, Rosen N.

Cancer Discov. 2018 Feb 26. doi: 10.1158/2159-8290.CD-17-1452. [Epub ahead of print]

PMID:
29483135
4.

c-RAF Ablation Induces Regression of Advanced Kras/Trp53 Mutant Lung Adenocarcinomas by a Mechanism Independent of MAPK Signaling.

Sanclemente M, Francoz S, Esteban-Burgos L, Bousquet-Mur E, Djurec M, Lopez-Casas PP, Hidalgo M, Guerra C, Drosten M, Musteanu M, Barbacid M.

Cancer Cell. 2018 Feb 12;33(2):217-228.e4. doi: 10.1016/j.ccell.2017.12.014. Epub 2018 Jan 27.

PMID:
29395869
5.

Saa3 is a key mediator of the protumorigenic properties of cancer-associated fibroblasts in pancreatic tumors.

Djurec M, Graña O, Lee A, Troulé K, Espinet E, Cabras L, Navas C, Blasco MT, Martín-Díaz L, Burdiel M, Li J, Liu Z, Vallespinós M, Sanchez-Bueno F, Sprick MR, Trumpp A, Sainz B Jr., Al-Shahrour F, Rabadan R, Guerra C, Barbacid M.

Proc Natl Acad Sci U S A. 2018 Feb 6;115(6):E1147-E1156. doi: 10.1073/pnas.1717802115. Epub 2018 Jan 19.

PMID:
29351990
6.

The European Cancer Patient's Bill of Rights, update and implementation 2016.

Højgaard L, Löwenberg B, Selby P, Lawler M, Banks I, Law K, Albreht T, Armand JP, Barbacid M, Barzach M, Bergh J, Cameron D, Conte P, de Braud F, de Gramont A, De Lorenzo F, Diehl V, Diler S, Erdem S, Geissler J, Gore-Booth J, Henning G, Horgan D, Jassem J, Johnson P, Kaasa S, Kapitein P, Karjalainen S, Kelly J, Kienesberger A, La Vecchia C, Lacombe D, Lindahl T, Luzzatto L, Malby R, Mastris K, Meunier F, Murphy M, Naredi P, Nurse P, Oliver K, Pearce J, Pelouchov J, Piccart M, Pinedo B, Spurrier-Bernard G, Sullivan R, Tabernero J, Van de Velde C, van Herk B, Vedsted P, Waldmann A, Weller D, Wilking N, Wilson R, Yared W, Zielinski C, Zur Hausen H, Le Chevalier T, Johnston P.

ESMO Open. 2017 Jan 6;1(6):e000127. doi: 10.1136/esmoopen-2016-000127. eCollection 2016. Review.

7.

Cyclin-Dependent Kinase 4 Regulates Adult Neural Stem Cell Proliferation and Differentiation in Response to Insulin.

Chirivella L, Kirstein M, Ferrón SR, Domingo-Muelas A, Durupt FC, Acosta-Umanzor C, Cano-Jaimez M, Pérez-Sánchez F, Barbacid M, Ortega S, Burks DJ, Fariñas I.

Stem Cells. 2017 Dec;35(12):2403-2416. doi: 10.1002/stem.2694. Epub 2017 Sep 3.

PMID:
28833887
8.

Inactivation of Capicua in adult mice causes T-cell lymphoblastic lymphoma.

Simón-Carrasco L, Graña O, Salmón M, Jacob HKC, Gutierrez A, Jiménez G, Drosten M, Barbacid M.

Genes Dev. 2017 Jul 15;31(14):1456-1468. doi: 10.1101/gad.300244.117. Epub 2017 Aug 21.

9.

A Braf kinase-inactive mutant induces lung adenocarcinoma.

Nieto P, Ambrogio C, Esteban-Burgos L, Gómez-López G, Blasco MT, Yao Z, Marais R, Rosen N, Chiarle R, Pisano DG, Barbacid M, Santamaría D.

Nature. 2017 Aug 10;548(7666):239-243. doi: 10.1038/nature23297. Epub 2017 Aug 2.

10.

Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.

Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N.

Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2.

11.

Genetically Engineered Mouse Models of K-Ras-Driven Lung and Pancreatic Tumors: Validation of Therapeutic Targets.

Drosten M, Guerra C, Barbacid M.

Cold Spring Harb Perspect Med. 2017 Aug 4. pii: a031542. doi: 10.1101/cshperspect.a031542. [Epub ahead of print]

PMID:
28778964
12.

A new mode of DNA binding distinguishes Capicua from other HMG-box factors and explains its mutation patterns in cancer.

Forés M, Simón-Carrasco L, Ajuria L, Samper N, González-Crespo S, Drosten M, Barbacid M, Jiménez G.

PLoS Genet. 2017 Mar 9;13(3):e1006622. doi: 10.1371/journal.pgen.1006622. eCollection 2017 Mar.

13.

H-Ras and K-Ras Oncoproteins Induce Different Tumor Spectra When Driven by the Same Regulatory Sequences.

Drosten M, Simón-Carrasco L, Hernández-Porras I, Lechuga CG, Blasco MT, Jacob HK, Fabbiano S, Potenza N, Bustelo XR, Guerra C, Barbacid M.

Cancer Res. 2017 Feb 1;77(3):707-718. doi: 10.1158/0008-5472.CAN-16-2925. Epub 2016 Nov 21.

14.

KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy.

Ambrogio C, Nadal E, Villanueva A, Gómez-López G, Cash TP, Barbacid M, Santamaría D.

ESMO Open. 2016 Sep 6;1(5):e000076. eCollection 2016. Review.

15.

In vivo oncogenic conflict triggered by co-existing KRAS and EGFR activating mutations in lung adenocarcinoma.

Ambrogio C, Barbacid M, Santamaría D.

Oncogene. 2017 Apr 20;36(16):2309-2318. doi: 10.1038/onc.2016.385. Epub 2016 Oct 24.

PMID:
27775074
16.

Severe Intellectual Disability and Enhanced Gamma-Aminobutyric Acidergic Synaptogenesis in a Novel Model of Rare RASopathies.

Papale A, d'Isa R, Menna E, Cerovic M, Solari N, Hardingham N, Cambiaghi M, Cursi M, Barbacid M, Leocani L, Fasano S, Matteoli M, Brambilla R.

Biol Psychiatry. 2017 Feb 1;81(3):179-192. doi: 10.1016/j.biopsych.2016.06.016. Epub 2016 Jun 27.

PMID:
27587266
17.

Ras and p53: An unsuspected liaison.

Drosten M, Barbacid M.

Mol Cell Oncol. 2015 Jan 23;3(2):e996001. doi: 10.1080/23723556.2014.996001. eCollection 2016 Mar.

18.

Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma.

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, Hidalgo M, Serrano M, Villanueva A, Santamaría D, Barbacid M.

Nat Med. 2016 Mar;22(3):270-7. doi: 10.1038/nm.4041. Epub 2016 Feb 8.

PMID:
26855149
19.

Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.

Drosten M, Barbacid M.

J Mol Med (Berl). 2016 Feb;94(2):121-35. doi: 10.1007/s00109-015-1360-5. Epub 2015 Nov 3. Review.

PMID:
26526121
20.

Therapeutic inhibition of TRF1 impairs the growth of p53-deficient K-RasG12V-induced lung cancer by induction of telomeric DNA damage.

García-Beccaria M, Martínez P, Méndez-Pertuz M, Martínez S, Blanco-Aparicio C, Cañamero M, Mulero F, Ambrogio C, Flores JM, Megias D, Barbacid M, Pastor J, Blasco MA.

EMBO Mol Med. 2015 Jul;7(7):930-49. doi: 10.15252/emmm.201404497.

21.

H-ras distribution and signaling in plasma membrane microdomains are regulated by acylation and deacylation events.

Agudo-Ibáñez L, Herrero A, Barbacid M, Crespo P.

Mol Cell Biol. 2015 Jun 1;35(11):1898-914. doi: 10.1128/MCB.01398-14. Epub 2015 Mar 16.

22.

Functional reprogramming of polyploidization in megakaryocytes.

Trakala M, Rodríguez-Acebes S, Maroto M, Symonds CE, Santamaría D, Ortega S, Barbacid M, Méndez J, Malumbres M.

Dev Cell. 2015 Jan 26;32(2):155-67. doi: 10.1016/j.devcel.2014.12.015.

23.

K-RasV14I recapitulates Noonan syndrome in mice.

Hernández-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Cañamero M, Cámara JA, Cussó L, Desco M, Heeschen C, Mulero F, Bustelo XR, Guerra C, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Nov 18;111(46):16395-400. doi: 10.1073/pnas.1418126111. Epub 2014 Oct 30.

24.

Lentiviral-based approach for the validation of cancer therapeutic targets in vivo.

Ambrogio C, Stern P, Scuoppo C, Kranz H, Barbacid M, Santamaría D.

Biotechniques. 2014 Oct 1;57(4):179, 181-7. doi: 10.2144/000114214. eCollection 2014 Oct.

25.

Loss of p53 induces cell proliferation via Ras-independent activation of the Raf/Mek/Erk signaling pathway.

Drosten M, Sum EY, Lechuga CG, Simón-Carrasco L, Jacob HK, García-Medina R, Huang S, Beijersbergen RL, Bernards R, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15155-60. doi: 10.1073/pnas.1417549111. Epub 2014 Oct 6.

26.

Modeling lung cancer evolution and preclinical response by orthotopic mouse allografts.

Ambrogio C, Carmona FJ, Vidal A, Falcone M, Nieto P, Romero OA, Puertas S, Vizoso M, Nadal E, Poggio T, Sánchez-Céspedes M, Esteller M, Mulero F, Voena C, Chiarle R, Barbacid M, Santamaría D, Villanueva A.

Cancer Res. 2014 Nov 1;74(21):5978-88. doi: 10.1158/0008-5472.CAN-14-1606. Epub 2014 Sep 12.

27.

Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.

Hermann PC, Sancho P, Cañamero M, Martinelli P, Madriles F, Michl P, Gress T, de Pascual R, Gandia L, Guerra C, Barbacid M, Wagner M, Vieira CR, Aicher A, Real FX, Sainz B Jr, Heeschen C.

Gastroenterology. 2014 Nov;147(5):1119-33.e4. doi: 10.1053/j.gastro.2014.08.002. Epub 2014 Aug 12.

PMID:
25127677
28.

Ras in epidermal proliferation.

Drosten M, Lechuga CG, Barbacid M.

Oncotarget. 2014 Jul 30;5(14):5194-5. No abstract available.

29.

Reply: 'Comments on Stromal disrupting effects of nab-paclitaxel in pancreatic cancer'.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2014 Oct 14;111(8):1677-8. doi: 10.1038/bjc.2014.129. Epub 2014 Mar 18. No abstract available.

30.

Genetic characterization of the role of the Cip/Kip family of proteins as cyclin-dependent kinase inhibitors and assembly factors.

Cerqueira A, Martín A, Symonds CE, Odajima J, Dubus P, Barbacid M, Santamaría D.

Mol Cell Biol. 2014 Apr;34(8):1452-9. doi: 10.1128/MCB.01163-13. Epub 2014 Feb 10.

31.

A catalyst for change: the European cancer Patient's Bill of Rights.

Lawler M, Le Chevalier T, Murphy MJ Jr, Banks I, Conte P, De Lorenzo F, Meunier F, Pinedo HM, Selby P, Armand JP, Barbacid M, Barzach M, Bergh J, Bode G, Cameron DA, de Braud F, de Gramont A, Diehl V, Diler S, Erdem S, Fitzpatrick JM, Geissler J, Hollywood D, Højgaard L, Horgan D, Jassem J, Johnson PW, Kapitein P, Kelly J, Kloezen S, La Vecchia C, Löwenberg B, Oliver K, Sullivan R, Tabernero J, Van de Velde CJ, Wilking N, Wilson R, Zielinski C, Zur Hausen H, Johnston PG.

Oncologist. 2014 Mar;19(3):217-24. doi: 10.1634/theoncologist.2013-0452. Epub 2014 Feb 3. No abstract available.

32.

Identification of cancer initiating cells in K-Ras driven lung adenocarcinoma.

Mainardi S, Mijimolle N, Francoz S, Vicente-Dueñas C, Sánchez-García I, Barbacid M.

Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):255-60. doi: 10.1073/pnas.1320383110. Epub 2013 Dec 23.

33.

Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications.

Azrak SS, Ginel-Picardo A, Drosten M, Barbacid M, Santos E.

BMC Genomics. 2013 Oct 25;14:731. doi: 10.1186/1471-2164-14-731.

34.

Genetic analysis of Ras genes in epidermal development and tumorigenesis.

Drosten M, Lechuga CG, Barbacid M.

Small GTPases. 2013 Oct-Dec;4(4):236-41. doi: 10.4161/sgtp.26905. Epub 2013 Oct 22. Review.

35.

Stromal disrupting effects of nab-paclitaxel in pancreatic cancer.

Alvarez R, Musteanu M, Garcia-Garcia E, Lopez-Casas PP, Megias D, Guerra C, Muñoz M, Quijano Y, Cubillo A, Rodriguez-Pascual J, Plaza C, de Vicente E, Prados S, Tabernero S, Barbacid M, Lopez-Rios F, Hidalgo M.

Br J Cancer. 2013 Aug 20;109(4):926-33. doi: 10.1038/bjc.2013.415. Epub 2013 Aug 1.

36.

Ras signaling is essential for skin development.

Drosten M, Lechuga CG, Barbacid M.

Oncogene. 2014 May 29;33(22):2857-65. doi: 10.1038/onc.2013.254. Epub 2013 Jul 8.

PMID:
23831572
37.

Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas.

González-Sánchez E, Martín-Caballero J, Flores JM, Hernández-Losa J; Ma Ángeles Montero, Cortés J, Mares R, Barbacid M, Recio JA.

PLoS One. 2013 Jun 25;8(6):e66933. doi: 10.1371/journal.pone.0066933. Print 2013.

38.

Concurrent deletion of cyclin E1 and cyclin-dependent kinase 2 in hepatocytes inhibits DNA replication and liver regeneration in mice.

Hu W, Nevzorova YA, Haas U, Moro N, Sicinski P, Geng Y, Barbacid M, Trautwein C, Liedtke C.

Hepatology. 2014 Feb;59(2):651-60. doi: 10.1002/hep.26584. Epub 2013 Dec 24.

39.

Genetically engineered mouse models of pancreatic adenocarcinoma.

Guerra C, Barbacid M.

Mol Oncol. 2013 Apr;7(2):232-47. doi: 10.1016/j.molonc.2013.02.002. Epub 2013 Feb 11. Review.

40.

Mouse models of cancer.

Berns A, Barbacid M.

Mol Oncol. 2013 Apr;7(2):143-5. doi: 10.1016/j.molonc.2013.02.014. Epub 2013 Feb 26. No abstract available.

41.

EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma.

Navas C, Hernández-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M.

Cancer Cell. 2012 Sep 11;22(3):318-30. doi: 10.1016/j.ccr.2012.08.001.

42.

Rapid identification of ETP-46992, orally bioavailable PI3K inhibitor, selective versus mTOR.

Martínez González S, Hernández AI, Varela C, Lorenzo M, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán MI, Alfonso P, García-Serelde B, Mateos G, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Blanco-Aparicio C, Pastor J.

Bioorg Med Chem Lett. 2012 Aug 15;22(16):5208-14. doi: 10.1016/j.bmcl.2012.06.093. Epub 2012 Jul 4.

PMID:
22819764
43.

Opening a new GATAway for treating KRAS-driven lung tumors.

Barbacid M.

Cancer Cell. 2012 May 15;21(5):598-600. doi: 10.1016/j.ccr.2012.04.032.

44.

Identification of ETP-46321, a potent and orally bioavailable PI3K α, δ inhibitor.

Martínez González S, Hernández AI, Varela C, Rodríguez-Arístegui S, Lorenzo M, Rodríguez A, Rivero V, Martín JI, Saluste CG, Ramos-Lima F, Cendón E, Cebrián D, Aguirre E, Gomez-Casero E, Albarrán M, Alfonso P, García-Serelde B, Oyarzabal J, Rabal O, Mulero F, Gonzalez-Granda T, Link W, Fominaya J, Barbacid M, Bischoff JR, Pizcueta P, Pastor J.

Bioorg Med Chem Lett. 2012 May 15;22(10):3460-6. doi: 10.1016/j.bmcl.2012.03.090. Epub 2012 Mar 29.

PMID:
22520259
45.

Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion.

Ganuza M, Sáiz-Ladera C, Cañamero M, Gómez G, Schneider R, Blasco MA, Pisano D, Paramio JM, Santamaría D, Barbacid M.

EMBO J. 2012 May 30;31(11):2498-510. doi: 10.1038/emboj.2012.94. Epub 2012 Apr 13.

46.

What we have learned about pancreatic cancer from mouse models.

Pérez-Mancera PA, Guerra C, Barbacid M, Tuveson DA.

Gastroenterology. 2012 May;142(5):1079-92. doi: 10.1053/j.gastro.2012.03.002. Epub 2012 Mar 8. Review. No abstract available.

PMID:
22406637
47.

Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras.

Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M, Barbacid M, Kolch W.

Mol Cell. 2011 Dec 23;44(6):893-906. doi: 10.1016/j.molcel.2011.10.016.

48.

Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors.

Murga M, Campaner S, Lopez-Contreras AJ, Toledo LI, Soria R, Montaña MF, Artista L, Schleker T, Guerra C, Garcia E, Barbacid M, Hidalgo M, Amati B, Fernandez-Capetillo O.

Nat Struct Mol Biol. 2011 Nov 27;18(12):1331-1335. doi: 10.1038/nsmb.2189.

49.

A pericyte origin of spinal cord scar tissue.

Göritz C, Dias DO, Tomilin N, Barbacid M, Shupliakov O, Frisén J.

Science. 2011 Jul 8;333(6039):238-42. doi: 10.1126/science.1203165.

50.

Pancreatitis-induced inflammation contributes to pancreatic cancer by inhibiting oncogene-induced senescence.

Guerra C, Collado M, Navas C, Schuhmacher AJ, Hernández-Porras I, Cañamero M, Rodriguez-Justo M, Serrano M, Barbacid M.

Cancer Cell. 2011 Jun 14;19(6):728-39. doi: 10.1016/j.ccr.2011.05.011.

Supplemental Content

Loading ...
Support Center